期刊文献+

来那度胺合成工艺研究 被引量:1

Study on the Synthetic Process of Lenalidomide
下载PDF
导出
摘要 本文以2-溴甲基-3-硝基苯甲酸甲酯与3-氨基哌啶-2,6-二酮盐酸盐缩合反应得到3-(4′-硝基-1-氧-1,3-二氢-2H-异吲哚-2-基)哌啶-2,6-二酮(L-IM1),L-IM1经醋酸铵、铁粉还原得到3-(4′-氨基-1-氧-1,3-二氢-2H-异吲哚-2-基)哌啶-2,6-二酮(L-IM2),L-IM2重结晶得到来那度胺,对每步合成及纯化进行了工艺优化,总收率为42.86%,纯度为99.8%,并用熔点、IR、LC-MS和1H NMR对产物进行了表征。 This article mainly studied the synthetic process and the optimization of the reaction conditions ofLenalidomide. Starting from methyl 2-bromomethyl-3-nitrobenzoate and 3-amino-2,6-piperidinedionehydrochloride, the intermediate product 3-(4-nitro-1-oxo-2-isoindolinyl) piperidine-2,6-dione( L-IM1) can be obtained via condensation reaction. Through reduction process in the presence of ammonium acetate andiron powder, 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline( L-IM2) which is crudeLenalidomide then can be obtained. By crystallization of L-IM2 we got the final product Lenalidomide. Each processof synthesis and purification was optimized. The total yield was 42. 86% and the purity was 99. 8%. And the productswere characterized by melting point, IR、LC-MS and 1 H-NMR.
作者 姚彤 Yao Tong(Lianyungang Jari Pharmaceutical Limited Company,Jiangsu Lianyungang 222005)
出处 《化工时刊》 CAS 2020年第6期10-14,共5页 Chemical Industry Times
关键词 来那度胺 免疫调节剂 合成 优化 Lenalidomide immunomodulator synthesize optimization
  • 相关文献

参考文献3

二级参考文献19

  • 1宋丽洁,封宇飞,傅得兴,胡欣,王唯红.新型免疫调节药来那度胺的药理及临床研究进展[J].中国新药杂志,2006,15(21):1889-1892. 被引量:14
  • 2ANDERSON KC. Lenalidomide and thalidomide: mechanisms of action-simularities and differences[ J]. Semin Hematol,2005,42 ( Suppl 4 ) : S3 - S8.
  • 3DREDGE K,MARRIOTT JB,MACDONALD CD,et al.Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects [ J ]. Br J Cancer, 2002,87 (10) :1166-1172.
  • 4RAGHAVENDRACHARYULU PV, VEERENDER M, AMARENDHAR M. An improved process for the preparation of lenalidomide : IN, 2006CH00047 [ P ]. ( CA 2008,149 : 402200).
  • 5MULLER GW,STIRLING DI ,CHEN RSC,et al. Substituted 2-(2,6- dioxopiperidin-3-yl) phthalimides and-1-oxoisoindo-lines and method of reducing TNF-α levels : WO ,9803502 [ P ]. 1998 - 01 - 29.
  • 6ABE M, AKIYAMA T, UMEZAWA Y, et al. Synthesis and biological activity of sulphostin analogues, novel dipeptidyl peptidase IV inhibitors [ J ]. Bioorg Med Chem,2005,13 ( 3 ) :785 - 797.
  • 7彭师奇,赵明,崔国辉,等.N-(3-羧基-9-苄基咔啉-1-基)乙基氨基酸,其合成方法及应用:CN,200810057219[P].2009-08-05.
  • 8药品注册管理办法[S].国家食品药品监督管理局令第28号,2007.
  • 9FDA. Chemistry review data sheet[ EB/OL ]. ( 2011 - 12 - 09 ). http://www, accessdata, fda. gov/drugsatfda docs/nda/2005/ 021880 s000_Revlimid_ChemR, pdf.
  • 10FDA. Clinical pharmacology and biopharmaceutics reviews [ EB/ OL ]. (2011 - 12 -09 ). http://www, aeeessdata, fda. gov/drug- satfda_docs/nda/2005/021880 s0OO_Revlimid_BioPharmR, pdf.

共引文献6

同被引文献4

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部